• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人源单链可变片段抗体抑制巨噬细胞移动抑制因子变构酶活性。

Human single-chain variable fragment antibody inhibits macrophage migration inhibitory factor tautomerase activity.

机构信息

Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Department of Biochemistry, Faculty of Sciences, Kasetsart University, Bangkok, Thailand.

出版信息

Int J Mol Med. 2014 Mar;33(3):515-22. doi: 10.3892/ijmm.2014.1622. Epub 2014 Jan 13.

DOI:10.3892/ijmm.2014.1622
PMID:24424397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3926510/
Abstract

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine, secreted from a variety of immune cells, that regulates innate and adaptive immune responses. Elevation of MIF levels in plasma correlates with the severity of inflammatory diseases in humans. Inhibition of MIF or its tautomerase activity ameliorates disease severity by reducing inflammatory responses. In this study, the human single-chain variable fragment (HuScFv) antibody specific to MIF was selected from the human antibody phage display library by using purified recombinant full-length human MIF (rMIF) as the target antigen. Monoclonal HuScFv was produced from phage-transformed bacteria and tested for their binding activities to rMIF by indirect enzyme-linked immunosorbent assay as well as to native MIF by western blot analysis and immunofluorescence assay. The HuScFv with highest binding signal to rMIF also inhibited the tautomerase activities of both rMIF and native MIF in human monoblastic leukemia (U937) cells in a dose-dependent manner. Mimotope searching and molecular docking concordantly demonstrated that the HuScFv interacted with Lys32 and Ile64 in the MIF tautomerase active site. To the best of our knowledge, this is the first study to focus on MIF-specific fully-human antibody fragment with a tautomerase-inhibitory effect that has potential to be developed as anti-inflammatory biomolecules for human use.

摘要

巨噬细胞移动抑制因子(MIF)是一种促炎细胞因子,由多种免疫细胞分泌,调节先天和适应性免疫反应。血浆中 MIF 水平的升高与人类炎症性疾病的严重程度相关。抑制 MIF 或其互变异构酶活性通过减少炎症反应来改善疾病严重程度。在这项研究中,用人重组全长人 MIF(rMIF)作为靶抗原,从人抗体噬菌体展示文库中筛选出针对 MIF 的人单链可变片段(HuScFv)抗体。从噬菌体转化的细菌中制备单克隆 HuScFv,并通过间接酶联免疫吸附试验以及 Western blot 分析和免疫荧光试验检测其与 rMIF 的结合活性和天然 MIF 的结合活性。与 rMIF 结合信号最强的 HuScFv 还能以剂量依赖的方式抑制人单核白血病(U937)细胞中 rMIF 和天然 MIF 的互变异构酶活性。模拟表位搜索和分子对接一致表明,HuScFv 与 MIF 互变异构酶活性部位的 Lys32 和 Ile64 相互作用。据我们所知,这是第一项研究针对具有互变异构酶抑制作用的 MIF 特异性全人抗体片段的研究,该抗体片段有可能被开发为用于人类的抗炎生物分子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/d4b10028c80c/IJMM-33-03-0515-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/3de906f92181/IJMM-33-03-0515-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/2317a6fb7046/IJMM-33-03-0515-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/7b43fa1a3a37/IJMM-33-03-0515-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/d4b10028c80c/IJMM-33-03-0515-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/3de906f92181/IJMM-33-03-0515-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/2317a6fb7046/IJMM-33-03-0515-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/7b43fa1a3a37/IJMM-33-03-0515-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdd/3926510/d4b10028c80c/IJMM-33-03-0515-g03.jpg

相似文献

1
Human single-chain variable fragment antibody inhibits macrophage migration inhibitory factor tautomerase activity.人源单链可变片段抗体抑制巨噬细胞移动抑制因子变构酶活性。
Int J Mol Med. 2014 Mar;33(3):515-22. doi: 10.3892/ijmm.2014.1622. Epub 2014 Jan 13.
2
The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents.巨噬细胞移动抑制因子的互变异构酶活性位点是发现新型抗炎剂的潜在靶点。
J Biol Chem. 2002 Jul 12;277(28):24976-82. doi: 10.1074/jbc.M203220200. Epub 2002 May 7.
3
Macrophage migration inhibitory factor (MIF) is rendered enzymatically inactive by myeloperoxidase-derived oxidants but retains its immunomodulatory function.巨噬细胞移动抑制因子(MIF)可被髓过氧化物酶衍生的氧化剂酶失活,但保留其免疫调节功能。
Free Radic Biol Med. 2015 Dec;89:498-511. doi: 10.1016/j.freeradbiomed.2015.09.009. Epub 2015 Oct 8.
4
Optimization of Pyrazoles as Phenol Surrogates to Yield Potent Inhibitors of Macrophage Migration Inhibitory Factor.优化吡唑作为酚替代物以生成有效的巨噬细胞移动抑制因子抑制剂。
ChemMedChem. 2018 Jun 6;13(11):1092-1097. doi: 10.1002/cmdc.201800158. Epub 2018 Apr 23.
5
Ellagic Acid, a Dietary Polyphenol, Inhibits Tautomerase Activity of Human Macrophage Migration Inhibitory Factor and Its Pro-inflammatory Responses in Human Peripheral Blood Mononuclear Cells.鞣花酸,一种膳食多酚,可抑制人巨噬细胞移动抑制因子的互变异构酶活性及其在人外周血单核细胞中的促炎反应。
J Agric Food Chem. 2015 May 27;63(20):4988-98. doi: 10.1021/acs.jafc.5b00921. Epub 2015 May 15.
6
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites.对乙酰氨基酚代谢物对巨噬细胞移动抑制因子(MIF)互变异构酶及生物学活性的抑制作用
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):144-9. doi: 10.1073/pnas.011569399. Epub 2002 Jan 2.
7
Multiple binding modes of isothiocyanates that inhibit macrophage migration inhibitory factor.抑制巨噬细胞移动抑制因子的异硫氰酸酯的多种结合模式。
Eur J Med Chem. 2015 Mar 26;93:501-10. doi: 10.1016/j.ejmech.2015.02.012. Epub 2015 Feb 24.
8
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity suppresses microglia-mediated inflammatory responses.抑制巨噬细胞迁移抑制因子(MIF)互变异构酶活性可抑制小胶质细胞介导的炎症反应。
Clin Exp Pharmacol Physiol. 2016 Nov;43(11):1134-1144. doi: 10.1111/1440-1681.12647.
9
Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors.巨噬细胞移动抑制因子与互变异构酶抑制剂的发现
Curr Pharm Des. 2002;8(14):1297-317. doi: 10.2174/1381612023394674.
10
Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments.巨噬细胞移动抑制因子(MIF)互变异构酶抑制剂作为潜在的新型抗炎药:当前进展
Curr Med Chem. 2009;16(9):1091-114. doi: 10.2174/092986709787581842.

引用本文的文献

1
[Exploring the mechanism of IgA vasculitis pathogenesis through the interaction of thrombin and inflammatory factors using urinary proteomics].利用尿液蛋白质组学通过凝血酶与炎症因子的相互作用探索IgA血管炎发病机制
Zhongguo Dang Dai Er Ke Za Zhi. 2024 Jul 15;26(7):683-689. doi: 10.7499/j.issn.1008-8830.2311151.
2
Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.新型半衰期延长的抗 MIF 纳米抗体可预防内毒素休克。
FASEB J. 2018 Jun;32(6):3411-3422. doi: 10.1096/fj.201701189R. Epub 2018 Jan 25.
3
MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus.

本文引用的文献

1
Novel anti-inflammatory activity of epoxyazadiradione against macrophage migration inhibitory factor: inhibition of tautomerase and proinflammatory activities of macrophage migration inhibitory factor.环氧补骨脂素对巨噬细胞移动抑制因子的抗炎新活性:抑制巨噬细胞移动抑制因子的互变异构酶和促炎活性。
J Biol Chem. 2012 Jul 13;287(29):24844-61. doi: 10.1074/jbc.M112.341321. Epub 2012 May 29.
2
Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF.通过完全人源抗体中和巨噬细胞移动抑制因子 (MIF) 与其针对 MIF β-折叠结构的特异性相关。
J Biol Chem. 2012 Mar 2;287(10):7446-55. doi: 10.1074/jbc.M111.329664. Epub 2012 Jan 11.
3
巨噬细胞移动抑制因子:在系统性红斑狼疮病理病因学中的意义
Front Immunol. 2015 Nov 11;6:577. doi: 10.3389/fimmu.2015.00577. eCollection 2015.
The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF).
D-多巴色素互变异构酶(DDT)基因产物是细胞因子,也是巨噬细胞移动抑制因子(MIF)的功能同源物。
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E577-85. doi: 10.1073/pnas.1102941108. Epub 2011 Aug 4.
4
Characterization, epitope identification and mechanisms of the anti-septic capacity of monoclonal antibodies against macrophage migration inhibitory factor.鉴定单克隆抗巨噬细胞移动抑制因子的杀菌能力、表位识别及作用机制。
Int Immunopharmacol. 2011 Sep;11(9):1333-40. doi: 10.1016/j.intimp.2011.04.017. Epub 2011 May 13.
5
MIF as a disease target: ISO-1 as a proof-of-concept therapeutic.MIF 作为疾病靶点:ISO-1 作为概念验证治疗方法。
Future Med Chem. 2011 Jan;3(1):45-63. doi: 10.4155/fmc.10.281.
6
A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease.一种用于治疗炎症性疾病的巨噬细胞移动抑制因子小分子抑制剂。
FASEB J. 2010 Nov;24(11):4459-66. doi: 10.1096/fj.10-162347. Epub 2010 Jul 12.
7
A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus.一种针对基质蛋白(M1)的人源单链转体可干扰甲型流感病毒的复制。
Bioconjug Chem. 2010 Jul 21;21(7):1134-41. doi: 10.1021/bc900251u.
8
Macrophage migration inhibitory factor (MIF): a promising biomarker.巨噬细胞移动抑制因子(MIF):一种有前景的生物标志物。
Drug News Perspect. 2010 May;23(4):257-64. doi: 10.1358/dnp.2010.23.4.1453629.
9
Autoimmune diseases: MIF as a therapeutic target.自身免疫性疾病:MIF 作为治疗靶点。
Expert Opin Ther Targets. 2010 Mar;14(3):253-64. doi: 10.1517/14728220903551304.
10
A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A.一种能够中和 A 型肉毒神经毒素锌金属蛋白酶活性的 VH H。
J Biol Chem. 2010 Mar 26;285(13):9657-9666. doi: 10.1074/jbc.M109.073163. Epub 2010 Jan 21.